Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245221 | 1.00 | DRD2 (0.53) | DRD2SMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL4239981 | 0.88 | DRD2 (0.50) | DRD2SMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL4239985 | 0.88 | DRD2 (0.50) | DRD2SMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL4252076 | 0.80 | HTR1A (0.72) | SMN1; SMN2HTR1A | |
| SCHEMBL4252077 | 0.80 | HTR1A (0.72) | SMN1; SMN2HTR1A | |
| SCHEMBL4245062 | 0.77 | SMN1; SMN2 (0.58) | DRD2SMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL4245064 | 0.77 | SMN1; SMN2 (0.58) | DRD2SMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL4242630 | 0.76 | DRD2 (0.51) | DRD2SMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL4242625 | 0.76 | DRD2 (0.51) | DRD2SMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL5739079 | 0.76 | HTR1A (0.52) | KMT2AALDH1A1KDM4EHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | claimed |
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | HTR1A, HTR5A, HTR2C | DRD2 214/4885SMN1; SMN2 1400/4885KMT2A 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.